Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients
{{output}}
Clinical trials on icotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), have shown promising results as targeted therapy for non-small cell lung cancer (NSCLC). This study aimed to establish an effective scoring s... ...
